Prevalence of SARS-CoV-2 antibodies in healthy blood donors from the state of Tyrol, Austria, in summer 2020.
Covid-19
Cross-sectional studies
Epidemiology
Seropositivity
Seroprevalence
Journal
Wiener klinische Wochenschrift
ISSN: 1613-7671
Titre abrégé: Wien Klin Wochenschr
Pays: Austria
ID NLM: 21620870R
Informations de publication
Date de publication:
Dec 2021
Dec 2021
Historique:
received:
24
06
2021
accepted:
28
09
2021
pubmed:
27
10
2021
medline:
17
12
2021
entrez:
26
10
2021
Statut:
ppublish
Résumé
Seroepidemiological studies provide important insight into the spread of severe acute respiratory syndrome coronavirus 2 (SARS-CoV‑2) in our society. We aimed to determine seropositivity of SARS-CoV‑2 antibodies and its cross-sectional correlates in a large cohort of blood donors. In this observational cohort study, we tested healthy blood donors residing in Tyrol, Austria, for SARS-CoV‑2 antibodies using the Abbott SARS-CoV‑2 IgG chemiluminescent microparticle immunoassay. We estimated 95% confidence intervals (95% CI) of seroprevalences using bootstrapping and tested for differences by participant characteristics using logistic regression. Between 8 June and 4 September 2020, we screened 5345 healthy individuals at local blood donor sessions (mean age 42.7 years, SD 13.5 years, 46.7% female). Overall seroprevalence was 3.1% (95% CI 2.7-3.6%, 165 cases), which is 5.1-fold higher (95% CI 4.5-6.0%) than the case number identified by the health authorities in the state-wide testing program (0.6%; 4536 out of 757,634). Seroprevalence was higher in the district Landeck (16.6%, P < 0.001) and in individuals aged < 25 years (4.7%, P = 0.043), but did not differ by gender, blood types, or medication intake. The odds ratio for seropositivity was 2.51 for participants who had travelled to Ischgl (1.49-4.21, P = 0.001), 1.39 who had travelled to other federal states (1.00-1.93, P = 0.052), and 2.41 who had travelled abroad (1.61-3.63, P < 0.001). Compared to participants who had a suspected/confirmed SARS-CoV‑2 infection but were seronegative, seropositive participants more frequently reported loss of smell (odds ratio = 2.49, 1.32-4.68, P = 0.005) and taste (odds ratio = 2.76, 1.54-4.92, P = 0.001). In summer 2020, SARS-CoV‑2 seroprevalence in Tyrolean blood donors was 3.1%. Our study revealed regional variation and associations with young age, travel history and specific symptoms.
Sections du résumé
BACKGROUND
BACKGROUND
Seroepidemiological studies provide important insight into the spread of severe acute respiratory syndrome coronavirus 2 (SARS-CoV‑2) in our society. We aimed to determine seropositivity of SARS-CoV‑2 antibodies and its cross-sectional correlates in a large cohort of blood donors.
METHODS
METHODS
In this observational cohort study, we tested healthy blood donors residing in Tyrol, Austria, for SARS-CoV‑2 antibodies using the Abbott SARS-CoV‑2 IgG chemiluminescent microparticle immunoassay. We estimated 95% confidence intervals (95% CI) of seroprevalences using bootstrapping and tested for differences by participant characteristics using logistic regression.
FINDINGS
RESULTS
Between 8 June and 4 September 2020, we screened 5345 healthy individuals at local blood donor sessions (mean age 42.7 years, SD 13.5 years, 46.7% female). Overall seroprevalence was 3.1% (95% CI 2.7-3.6%, 165 cases), which is 5.1-fold higher (95% CI 4.5-6.0%) than the case number identified by the health authorities in the state-wide testing program (0.6%; 4536 out of 757,634). Seroprevalence was higher in the district Landeck (16.6%, P < 0.001) and in individuals aged < 25 years (4.7%, P = 0.043), but did not differ by gender, blood types, or medication intake. The odds ratio for seropositivity was 2.51 for participants who had travelled to Ischgl (1.49-4.21, P = 0.001), 1.39 who had travelled to other federal states (1.00-1.93, P = 0.052), and 2.41 who had travelled abroad (1.61-3.63, P < 0.001). Compared to participants who had a suspected/confirmed SARS-CoV‑2 infection but were seronegative, seropositive participants more frequently reported loss of smell (odds ratio = 2.49, 1.32-4.68, P = 0.005) and taste (odds ratio = 2.76, 1.54-4.92, P = 0.001).
CONCLUSION
CONCLUSIONS
In summer 2020, SARS-CoV‑2 seroprevalence in Tyrolean blood donors was 3.1%. Our study revealed regional variation and associations with young age, travel history and specific symptoms.
Identifiants
pubmed: 34698961
doi: 10.1007/s00508-021-01963-3
pii: 10.1007/s00508-021-01963-3
pmc: PMC8546400
doi:
Substances chimiques
Antibodies, Viral
0
Types de publication
Journal Article
Observational Study
Langues
eng
Sous-ensembles de citation
IM
Pagination
1272-1280Informations de copyright
© 2021. The Author(s).
Références
N Engl J Med. 2020 Apr 30;382(18):1708-1720
pubmed: 32109013
J Clin Microbiol. 2020 Jul 23;58(8):
pubmed: 32381641
Sci Rep. 2021 May 12;11(1):10158
pubmed: 33980950
Vox Sang. 2021 Mar;116(3):296-304
pubmed: 33165917
Infection. 2021 Dec;49(6):1187-1194
pubmed: 34132990
Euro Surveill. 2020 Jun;25(24):
pubmed: 32583766
Science. 2020 Dec 4;370(6521):1227-1230
pubmed: 33115920
Vaccines (Basel). 2020 Dec 28;9(1):
pubmed: 33379160
Lancet Infect Dis. 2020 Sep;20(9):1015-1016
pubmed: 32304629
Biol Sex Differ. 2020 May 25;11(1):29
pubmed: 32450906
Lancet Child Adolesc Health. 2020 Sep;4(9):653-661
pubmed: 32593339
J Hypertens. 2020 May;38(5):781-782
pubmed: 32195824
Blood. 2020 Nov 26;136(22):2588-2591
pubmed: 33001206
Allergy. 2021 Mar;76(3):878-883
pubmed: 32734595
EBioMedicine. 2021 Aug;70:103534
pubmed: 34392147
Clin Chem Lab Med. 2021 Jan 15;59(6):1143-1154
pubmed: 33554557
Nat Commun. 2020 Sep 17;11(1):4698
pubmed: 32943630
Euro Surveill. 2020 Mar;25(11):
pubmed: 32186277
Wien Klin Wochenschr. 2020 Nov;132(21-22):645-652
pubmed: 32816114
Commun Med (London). 2021;1(1):4
pubmed: 34870284
Antiviral Res. 2020 Sep;181:104880
pubmed: 32679056
Infect Chemother. 2020 Jun;52(2):154-164
pubmed: 32537961
Cell Rep Med. 2020 Oct 20;1(7):100126
pubmed: 33015650